SG10201510245SA - Insulinotropic peptide derivative wherein its n-terminal amino acid is modified - Google Patents

Insulinotropic peptide derivative wherein its n-terminal amino acid is modified

Info

Publication number: SG10201510245SA
Authority: SG; Singapore
Prior art keywords: modified; amino acid; terminal amino; peptide derivative; insulinotropic peptide
Prior art date: 2007-07-16

Application number

SG10201510245SA

Inventor

Dae Hae Song

Chang Ki Lim

Young Hoon Kim

Se Chang Kwon

Gwan Sun Lee

Sung Min Bae

Sung Youb Jung

Original Assignee

Hanmi Science Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-16

Filing date

2008-07-16

Publication date

2016-01-28

2008-07-16 Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd

2016-01-28 Publication of SG10201510245SA publication Critical patent/SG10201510245SA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Vascular Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

SG10201510245SA 2007-07-16 2008-07-16 Insulinotropic peptide derivative wherein its n-terminal amino acid is modified SG10201510245SA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20070071071		2007-07-16
US99115507P	2007-11-29	2007-11-29

Publications (1)

Publication Number	Publication Date
SG10201510245SA true SG10201510245SA (en)	2016-01-28

Family

ID=40260219

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG10201510249PA SG10201510249PA (en)	2007-07-16	2008-07-16	Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
SG2012052114A SG183033A1 (en)	2007-07-16	2008-07-16	Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
SG10201510245SA SG10201510245SA (en)	2007-07-16	2008-07-16	Insulinotropic peptide derivative wherein its n-terminal amino acid is modified

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
SG10201510249PA SG10201510249PA (en)	2007-07-16	2008-07-16	Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
SG2012052114A SG183033A1 (en)	2007-07-16	2008-07-16	Insulinotropic peptide derivative wherein its n-terminal amino acid is modified

Country Status (21)

Country	Link
US (1)	US9422349B2 (en)
EP (4)	EP2537861B1 (en)
JP (7)	JP2009019027A (en)
KR (1)	KR101231431B1 (en)
CN (2)	CN101778863A (en)
AR (1)	AR067555A1 (en)
AU (1)	AU2008276762A1 (en)
BR (1)	BRPI0814097A8 (en)
CA (3)	CA2789112C (en)
DK (1)	DK2390265T3 (en)
ES (3)	ES2444622T3 (en)
IL (1)	IL203288A (en)
MY (1)	MY167486A (en)
NZ (3)	NZ594853A (en)
PH (2)	PH12014500922A1 (en)
PT (1)	PT2390265E (en)
RU (1)	RU2442792C2 (en)
SG (3)	SG10201510249PA (en)
TW (3)	TWI454276B (en)
WO (1)	WO2009011544A2 (en)
ZA (1)	ZA201000125B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2009019027A (en) *	2007-07-16	2009-01-29	Hanmi Pharmaceutical Co Ltd	Insulin-secreting peptide derivatives with amino-terminal amino acid mutations
DK2408800T3 (en)	2009-03-20	2016-08-29	Hanmi Science Co Ltd	A process for the preparation of a site-specific conjugate of a physiologically active polypeptide
KR20120116942A (en)	2009-11-23	2012-10-23	아밀린 파마슈티칼스, 인크.	Polypeptide conjugate
RU2422461C1 (en) *	2010-02-09	2011-06-27	Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет	Exenatid analogues
KR101382593B1 (en) *	2010-07-21	2014-04-10	한미사이언스 주식회사	Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
ES2563091T3 (en)	2010-09-28	2016-03-10	Amylin Pharmaceuticals, Llc	Genetically modified polypeptides that have enhanced duration of action
PT2621519T (en)	2010-09-28	2017-10-04	Aegerion Pharmaceuticals Inc	Leptin-abd fusion polypeptides with enhanced duration of action
US20140221282A1 (en)	2011-05-25	2014-08-07	Astrazeneca Pharmaceuticals Lp	Long duration dual hormone conjugates
UA113626C2 (en)	2011-06-02	2017-02-27		A COMPOSITION FOR THE TREATMENT OF DIABETES CONTAINING THE DURABLE INSULIN CON conjugate AND THE DUAL ACTION INSULINOTROPIC PIPIDE
CN103957926B (en)	2011-07-08	2018-07-03	安米林药品有限责任公司	Engineered polypeptides with enhanced duration of action and reduced immunogenicity
JP6006309B2 (en)	2011-07-08	2016-10-12	アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc	Engineered polypeptides with increased duration of action and reduced immunogenicity
KR20130049671A (en)	2011-11-04	2013-05-14	한미사이언스 주식회사	Method for preparation of biological active polypeptide conjugate
AR090281A1 (en)	2012-03-08	2014-10-29	Hanmi Science Co Ltd	IMPROVED PROCESS FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX
CN103130889A (en) *	2012-06-15	2013-06-05	中国药科大学	Exendin-4 analogue, preparation method thereof and application Exendin-4 analogue
US10441665B2 (en)	2012-07-25	2019-10-15	Hanmi Pharm. Co., Ltd.	Liquid formulation of long acting insulinotropic peptide conjugate
AR094821A1 (en)	2012-07-25	2015-09-02	Hanmi Pharm Ind Co Ltd	LIQUID FORMULATION OF AN INSULINOTROPIC PEPTIDE CONJUGATE OF PROLONGED ACTION
AR092862A1 (en)	2012-07-25	2015-05-06	Hanmi Pharm Ind Co Ltd	LIQUID FORMULATION OF PROLONGED ACTION INSULIN AND AN INSULINOTROPIC PEPTIDE AND PREPARATION METHOD
KR20140088837A (en) *	2013-01-03	2014-07-11	한미약품 주식회사	Insulinotropic peptide derivative wherein its N-terminal charge is modified
AR096891A1 (en)	2013-07-12	2016-02-03	Hanmi Pharm Ind Co Ltd	CONJUGATE OF BIOMOLOGICALLY ACTIVE POLYPEPTIDE MONOMER AND CONJUGATE OF FRAGMENTO FC OF IMMUNOGLOBULINA, THAT SHOWS CLEARING THROUGH REDUCED RECEPTOR, AND THE METHOD FOR PREPARING THE SAME
AR096890A1 (en)	2013-07-12	2016-02-03	Hanmi Pharm Ind Co Ltd	CONJUGATING FC OF IMMUNOGLOBULINA, THAT MAINTAINS THE UNION AFFINITY OF THE FC FRAGMENT OF THE IMMUNOGLOBULIN TO FCRN
PE20161153A1 (en)	2014-01-20	2016-10-27	Hanmi Pharm Ind Co Ltd	LONG-ACTING INSULIN AND USE OF THE SAME
EP4464332A1 (en)	2014-03-31	2024-11-20	Hanmi Pharm. Co., Ltd.	Composition for improving the solubility of a protein or peptide by using immunoglobulin fc fragment linkage
AR100639A1 (en)	2014-05-29	2016-10-19	Hanmi Pharm Ind Co Ltd	COMPOSITION TO TREAT DIABETES THAT INCLUDES CONJUGATES OF PROLONGED INSULIN ANALOGS AND CONJUGATES OF PROLONGED INSULINOTROPIC PEPTIDES
TWI684458B (en)	2014-05-30	2020-02-11	南韓商韓美藥品股份有限公司	Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist
EP3325496B1 (en)	2015-07-24	2024-02-07	Hanmi Pharm. Co., Ltd.	Method of preparing physiologically active polypeptide conjugate
UY36870A (en)	2015-08-28	2017-03-31	Hanmi Pharm Ind Co Ltd	NEW INSULIN ANALOGS
WO2017075505A2 (en) *	2015-10-28	2017-05-04	Tufts University	Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
RU2764197C1 (en)	2016-09-23	2022-01-14	Ханми Фарм. Ко., Лтд.	Insulin analogues with reduced affinity to insulin receptor and their use
WO2018105988A1 (en)	2016-12-05	2018-06-14	한미약품 주식회사	Conjugate having attenuated immune response
WO2018143729A1 (en)	2017-02-03	2018-08-09	한미약품 주식회사	Conjugate of bioactive material having enhanced sustainability and use thereof
WO2018174668A2 (en)	2017-03-23	2018-09-27	한미약품 주식회사	Insulin analog complex with reduced affinity for insulin receptor and use thereof
AU2021409610A1 (en) *	2020-12-24	2023-07-06	Hanmi Pharm. Co., Ltd.	Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome
WO2022266467A2 (en)	2021-06-17	2022-12-22	Dana-Farber Cancer Institute, Inc.	Recombinant histone polypeptide and uses thereof
KR20230000682A (en)	2021-06-25	2023-01-03	한미약품 주식회사	Efpeglenatide for reducing the risk of developing cardiovascular diseases or renal dysfunction
KR20230010571A (en)	2021-07-12	2023-01-19	한미약품 주식회사	A composition for oral administration comprising GLP-1 analog
US20250236850A1 (en) *	2022-04-08	2025-07-24	Danmarks Tekniske Universitet	Histidine methyltransferase for increased peptide and protein stability

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7A (en) *		1836-08-10	Thomas Blanchard	Machine for boring holes and cutting lanyard-scores in deadeyes
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
US5424286A (en)	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5424686A (en)	1994-04-20	1995-06-13	Philips Electronics North America Corporation	Negative-resistance-compensated microwave buffer
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DK0915910T3 (en)	1996-06-05	2006-05-22	Roche Diagnostics Gmbh	Exendin analogues, processes for their preparation, and drugs containing them
JP2002507188A (en)	1996-08-30	2002-03-05	イーライ・リリー・アンド・カンパニー	Use of glucagon-like peptide-1 (GLP-1) or a homolog thereof to prevent catabolic modulation after surgery
US7235627B2 (en)	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
ES2283025T3 (en) *	1996-08-30	2007-10-16	Novo Nordisk A/S	DERIVATIVES OF GLP-1.1.
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
DE69831673C5 (en)	1997-01-07	2015-01-22	Amylin Pharmaceuticals, Llc	USE OF EXEDINES AND THEIR ANTAGONISTS TO REDUCE FOOD CONSUMPTION
US7157555B1 (en)	1997-08-08	2007-01-02	Amylin Pharmaceuticals, Inc.	Exendin agonist compounds
EP1938831A1 (en)	1997-08-08	2008-07-02	Amylin Pharmaceuticals, Inc.	Novel exendin agonist compounds
CA2299425A1 (en) *	1997-08-08	1999-02-18	Amylin Pharmaceuticals, Inc.	Novel exendin agonist compounds
US7220721B1 (en) *	1997-11-14	2007-05-22	Amylin Pharmaceuticals, Inc.	Exendin agonist peptides
US6703359B1 (en)	1998-02-13	2004-03-09	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and GLP-1
WO1999043708A1 (en)	1998-02-27	1999-09-02	Novo Nordisk A/S	Glp-1 derivatives of glp-1 and exendin with protracted profile of action
IL141241A0 (en)	1998-08-28	2002-03-10	Lilly Co Eli	Method for administering insulinotropic peptides
EP1355942B1 (en)	2000-12-07	2008-08-27	Eli Lilly And Company	Glp-1 fusion proteins
IL141647A0 (en)	2001-02-26	2002-03-10	Yeda Res & Dev	Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US6573237B2 (en)	2001-03-16	2003-06-03	Eli Lilly And Company	Protein formulations
JP4417113B2 (en)	2002-02-20	2010-02-17	エミスフェアー・テクノロジーズ・インク	Administration method of GLP-1 molecule
WO2004035623A2 (en) *	2002-10-02	2004-04-29	Zealand Pharma A/S	Stabilized exendin-4 compounds
WO2004056313A2 (en) *	2002-12-17	2004-07-08	Amylin Pharmaceuticals, Inc.	Prevention and treatment of cardiac arrhythmias
US7790681B2 (en) *	2002-12-17	2010-09-07	Amylin Pharmaceuticals, Inc.	Treatment of cardiac arrhythmias with GLP-1 receptor ligands
JP2006514649A (en) *	2003-12-17	2006-05-11	アミリン・ファーマシューティカルズ，インコーポレイテッド	Composition for the treatment and prevention of nephropathy
TW200611704A (en)	2004-07-02	2006-04-16	Bristol Myers Squibb Co	Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
AU2006224537A1 (en) *	2005-03-18	2006-09-21	Novo Nordisk A/S	Extended GLP-1 compounds
PL2347762T3 (en) *	2005-08-19	2019-09-30	Amylin Pharmaceuticals, Llc	Exendin for treating diabetes and reducing body weight
JPWO2007063907A1 (en)	2005-11-30	2009-05-07	塩野義製薬株式会社	Peptide sugar chain adduct and pharmaceutical comprising the same as an active ingredient
EP2066337A2 (en) *	2006-08-04	2009-06-10	Amylin Pharmaceuticals, Inc.	Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
JP2008169195A (en) *	2007-01-05	2008-07-24	Hanmi Pharmaceutical Co Ltd	Insulin secretory peptide drug conjugates using carrier substances
WO2008145721A2 (en) *	2007-06-01	2008-12-04	Novo Nordisk A/S	N-terminal modification of polypeptides for protection against degradation by aminopeptidases
JP2009019027A (en) *	2007-07-16	2009-01-29	Hanmi Pharmaceutical Co Ltd	Insulin-secreting peptide derivatives with amino-terminal amino acid mutations
US9816387B2 (en)	2014-09-09	2017-11-14	United Technologies Corporation	Attachment faces for clamped turbine stator of a gas turbine engine

2007
- 2007-10-03 JP JP2007259853A patent/JP2009019027A/en active Pending
2008
- 2008-07-16 EP EP12185376.6A patent/EP2537861B1/en active Active
- 2008-07-16 CN CN200880024892A patent/CN101778863A/en active Pending
- 2008-07-16 PT PT111621322T patent/PT2390265E/en unknown
- 2008-07-16 NZ NZ594853A patent/NZ594853A/en unknown
- 2008-07-16 ES ES11162132.2T patent/ES2444622T3/en active Active
- 2008-07-16 AR ARP080103043A patent/AR067555A1/en active IP Right Grant
- 2008-07-16 TW TW097126905A patent/TWI454276B/en active
- 2008-07-16 RU RU2010101232/10A patent/RU2442792C2/en active
- 2008-07-16 MY MYPI2010000187A patent/MY167486A/en unknown
- 2008-07-16 TW TW101140650A patent/TWI532496B/en active
- 2008-07-16 DK DK11162132.2T patent/DK2390265T3/en active
- 2008-07-16 ES ES12185370.9T patent/ES2528346T3/en active Active
- 2008-07-16 EP EP08778827A patent/EP2176289A4/en not_active Withdrawn
- 2008-07-16 CA CA2789112A patent/CA2789112C/en active Active
- 2008-07-16 NZ NZ582471A patent/NZ582471A/en unknown
- 2008-07-16 BR BRPI0814097A patent/BRPI0814097A8/en not_active Application Discontinuation
- 2008-07-16 AU AU2008276762A patent/AU2008276762A1/en not_active Abandoned
- 2008-07-16 SG SG10201510249PA patent/SG10201510249PA/en unknown
- 2008-07-16 KR KR1020080069234A patent/KR101231431B1/en active Active
- 2008-07-16 EP EP12185370.9A patent/EP2537860B1/en active Active
- 2008-07-16 JP JP2010516925A patent/JP5481377B2/en active Active
- 2008-07-16 CA CA2693154A patent/CA2693154C/en active Active
- 2008-07-16 SG SG2012052114A patent/SG183033A1/en unknown
- 2008-07-16 SG SG10201510245SA patent/SG10201510245SA/en unknown
- 2008-07-16 CA CA2789123A patent/CA2789123C/en active Active
- 2008-07-16 NZ NZ596828A patent/NZ596828A/en unknown
- 2008-07-16 EP EP11162132.2A patent/EP2390265B1/en active Active
- 2008-07-16 ES ES12185376.6T patent/ES2528347T3/en active Active
- 2008-07-16 WO PCT/KR2008/004170 patent/WO2009011544A2/en not_active Ceased
- 2008-07-16 CN CN201510053063.8A patent/CN104672319B/en active Active
- 2008-07-16 US US12/669,372 patent/US9422349B2/en active Active
- 2008-07-16 TW TW101140652A patent/TWI524896B/en active
2010
- 2010-01-07 ZA ZA2010/00125A patent/ZA201000125B/en unknown
- 2010-01-13 IL IL203288A patent/IL203288A/en active IP Right Grant
2012
- 2012-09-03 JP JP2012193521A patent/JP6023516B2/en active Active
- 2012-09-03 JP JP2012193520A patent/JP6023515B2/en active Active
2013
- 2013-12-20 JP JP2013264258A patent/JP2014094948A/en active Pending
2014
- 2014-04-25 PH PH12014500922A patent/PH12014500922A1/en unknown
- 2014-04-25 PH PH12014500923A patent/PH12014500923A1/en unknown
2015
- 2015-05-07 JP JP2015095145A patent/JP2015166368A/en not_active Withdrawn
- 2015-05-07 JP JP2015095154A patent/JP2015172058A/en not_active Withdrawn

Also Published As

Publication number	Publication date
WO2009011544A2 (en)	2009-01-22
MY167486A (en)	2018-08-30
ES2528346T3 (en)	2015-02-09
JP5481377B2 (en)	2014-04-23
EP2390265A3 (en)	2012-03-21
ZA201000125B (en)	2011-04-28
CA2693154A1 (en)	2009-01-22
EP2537861B1 (en)	2014-11-26
TW200922615A (en)	2009-06-01
JP2015172058A (en)	2015-10-01
CN104672319B (en)	2020-03-10
TWI532496B (en)	2016-05-11
EP2176289A2 (en)	2010-04-21
US9422349B2 (en)	2016-08-23
NZ596828A (en)	2012-03-30
EP2537860A1 (en)	2012-12-26
JP2013014598A (en)	2013-01-24
SG183033A1 (en)	2012-08-30
CN101778863A (en)	2010-07-14
TW201311273A (en)	2013-03-16
NZ582471A (en)	2012-01-12
EP2537860B1 (en)	2014-11-26
JP2009019027A (en)	2009-01-29
JP2015166368A (en)	2015-09-24
JP2014094948A (en)	2014-05-22
PH12014500923A1 (en)	2016-03-07
HK1207088A1 (en)	2016-01-22
US20100204451A1 (en)	2010-08-12
ES2444622T3 (en)	2014-02-26
CA2789112C (en)	2015-01-20
NZ594853A (en)	2012-03-30
CN104672319A (en)	2015-06-03
TWI524896B (en)	2016-03-11
DK2390265T3 (en)	2014-02-10
AU2008276762A1 (en)	2009-01-22
EP2390265B1 (en)	2013-11-06
EP2176289A4 (en)	2010-10-27
WO2009011544A3 (en)	2009-03-19
CA2789123C (en)	2015-01-06
JP2010533709A (en)	2010-10-28
AR067555A1 (en)	2009-10-14
KR20090008151A (en)	2009-01-21
KR101231431B1 (en)	2013-02-07
SG10201510249PA (en)	2016-01-28
BRPI0814097A8 (en)	2016-01-12
RU2442792C2 (en)	2012-02-20
RU2010101232A (en)	2011-07-27
CA2693154C (en)	2014-09-09
EP2537861A1 (en)	2012-12-26
JP6023515B2 (en)	2016-11-09
EP2390265A2 (en)	2011-11-30
TWI454276B (en)	2014-10-01
PT2390265E (en)	2014-02-12
ES2528347T3 (en)	2015-02-09
JP6023516B2 (en)	2016-11-09
TW201311272A (en)	2013-03-16
CA2789123A1 (en)	2009-01-22
IL203288A (en)	2016-02-29
PH12014500922A1 (en)	2016-03-07
CA2789112A1 (en)	2009-01-22
BRPI0814097A2 (en)	2015-02-03
JP2013010779A (en)	2013-01-17

Publication	Publication Date	Title
ZA201000125B (en)	2011-04-28	Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
IL220161A0 (en)	2012-07-31	Oxyntomodulin peptide analogue
ZA201003681B (en)	2015-12-23	Compositions and methods comprising basic amino acid peptides and proteases
IL215348A0 (en)	2011-12-29	Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
EP2116238A4 (en)	2014-04-09	Amino acid composition
EP2298801A4 (en)	2011-08-03	Glycosylated glp-1 peptide
ZA200810072B (en)	2009-12-30	Insulinotropic peptide synthesis
EP2017283A4 (en)	2015-12-30	Peptide
EP2447264A4 (en)	2012-12-12	N-substituted-cyclic amino derivative
SI2207790T1 (en)	2013-11-29	Biologically active c-terminal arginine-containing peptides
PL2464656T3 (en)	2015-12-31	Novel peptide and use thereof
IL212078A0 (en)	2011-06-30	Antibodies to modified human igf-1/e peptides
EP2123666A4 (en)	2011-01-05	Peptide
GB0713189D0 (en)	2007-08-15	Amino acid derivatives
ZA201102450B (en)	2011-12-28	Amino acid derivative
GB0715712D0 (en)	2007-09-19	Amino acid derivatives
EP2036918A4 (en)	2011-01-19	Peptide derivative
GB0724953D0 (en)	2008-01-30	Methods of peptide modification
ZA200809190B (en)	2009-08-26	Amino acid surrogates for peptide constructs
GB0602780D0 (en)	2006-03-22	Amino Acid Derivatives
EP2258393A4 (en)	2012-02-15	Abc transporter protein expression inhibitor
GB0618748D0 (en)	2006-11-01	Peptide
PL2240200T3 (en)	2016-12-30	Therapeutic mannan linked mylein basic protein peptide mbp83-99
GB0605774D0 (en)	2006-05-03	Peptide
GB0812586D0 (en)	2008-08-13	Chimaeric peptide